Amgen Stock Forecast, Price & News

25 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Amgen in the last twelve months. There are currently 2 sell ratings, 9 hold ratings and 14 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" Amgen stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in AMGN, but not buy additional shares or sell existing shares.
View analyst ratings for Amgen or view top-rated stocks.

Wall Street analysts have given Amgen a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Amgen wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Amgen saw a drop in short interest in the month of May. As of May 28th, there was short interest totaling 10,040,000 shares, a drop of 12.4% from the May 13th total of 11,460,000 shares. Based on an average daily trading volume, of 2,770,000 shares, the days-to-cover ratio is currently 3.6 days. Currently, 1.8% of the shares of the stock are sold short.
View Amgen's Short Interest.

Amgen is scheduled to release its next quarterly earnings announcement on Tuesday, July 27th 2021.
View our earnings forecast for Amgen.

Amgen Inc. (NASDAQ:AMGN) issued its quarterly earnings data on Monday, April, 26th. The medical research company reported $3.70 earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of $4.05 by $0.35. The medical research company had revenue of $5.90 billion for the quarter, compared to the consensus estimate of $6.30 billion. Amgen had a trailing twelve-month return on equity of 93.84% and a net margin of 28.16%. The firm's revenue for the quarter was down 4.2% on a year-over-year basis. During the same period in the previous year, the business earned $4.17 earnings per share.
View Amgen's earnings history.

Amgen's stock was trading at $198.65 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, AMGN shares have increased by 20.2% and is now trading at $238.68.
View which stocks have been most impacted by COVID-19.

Amgen announced a quarterly dividend on Wednesday, March 3rd. Stockholders of record on Monday, May 17th will be paid a dividend of $1.76 per share on Tuesday, June 8th. This represents a $7.04 dividend on an annualized basis and a dividend yield of 2.95%. The ex-dividend date of this dividend is Friday, May 14th.
View Amgen's dividend history.

Amgen pays an annual dividend of $7.04 per share and currently has a dividend yield of 2.92%. Amgen does not yet have a strong track record of dividend growth. The dividend payout ratio of Amgen is 42.41%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, Amgen will have a dividend payout ratio of 39.51% next year. This indicates that Amgen will be able to sustain or increase its dividend.
View Amgen's dividend history.

Amgen updated its FY 2021 earnings guidance on Tuesday, May, 4th. The company provided EPS guidance of 16.000-17.000 for the period, compared to the Thomson Reuters consensus EPS estimate of $16.800. The company issued revenue guidance of $25.80 billion-$26.60 billion, compared to the consensus revenue estimate of $26.41 billion.

25 analysts have issued 1 year price objectives for Amgen's stock. Their forecasts range from $200.00 to $301.00. On average, they expect Amgen's stock price to reach $256.81 in the next twelve months. This suggests a possible upside of 7.6% from the stock's current price.
View analysts' price targets for Amgen or view top-rated stocks among Wall Street analysts.

806 employees have rated Amgen CEO Robert A. Bradway on Glassdoor.com. Robert A. Bradway has an approval rating of 91% among Amgen's employees. This puts Robert A. Bradway in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Amgen include Gilead Sciences (GILD), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Vertex Pharmaceuticals (VRTX), Alexion Pharmaceuticals (ALXN), Seagen (SGEN), Exact Sciences (EXAS), Alnylam Pharmaceuticals (ALNY), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Novavax (NVAX), Repligen (RGEN), Neurocrine Biosciences (NBIX), United Therapeutics (UTHR) and Exelixis (EXEL).
View all of AMGN's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Amgen investors own include Johnson & Johnson (JNJ), NVIDIA (NVDA), Intel (INTC), Cisco Systems (CSCO), Pfizer (PFE), AbbVie (ABBV), The Walt Disney (DIS), AT&T (T), Alibaba Group (BABA) and The Home Depot (HD).

Amgen trades on the NASDAQ under the ticker symbol "AMGN."

Amgen's stock is owned by a variety of institutional and retail investors. Top institutional investors include BlackRock Inc. (8.49%), Primecap Management Co. CA (2.90%), Morgan Stanley (1.73%), Geode Capital Management LLC (1.68%), Northern Trust Corp (1.35%) and Bank of New York Mellon Corp (1.11%). Company insiders that own Amgen stock include Cynthia M Patton, David Piacquad, David W Meline, Jonathan P Graham, Nancy A Grygiel, R Sanders Williams and Ronald D Sugar.
View institutional ownership trends for Amgen.

AMGN stock was sold by a variety of institutional investors in the last quarter, including Great West Life Assurance Co. Can, Nuveen Asset Management LLC, Woodline Partners LP, Capital International Investors, Primecap Management Co. CA, DekaBank Deutsche Girozentrale, Fiera Capital Corp, and APG Asset Management N.V.. Company insiders that have sold Amgen company stock in the last year include Jonathan P Graham, Nancy A Grygiel, R Sanders Williams, and Ronald D Sugar.
View insider buying and selling activity for Amgen or view top insider-selling stocks.

AMGN stock was bought by a variety of institutional investors in the last quarter, including FIL Ltd, Franklin Resources Inc., BlackRock Inc., Geode Capital Management LLC, Canada Pension Plan Investment Board, Prentice Wealth Management LLC, Nordea Investment Management AB, and Wilkinson Global Asset Management LLC.
View insider buying and selling activity for Amgen or or view top insider-buying stocks.

Shares of AMGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of AMGN stock can currently be purchased for approximately $238.68.

Amgen has a market capitalization of $137.13 billion and generates $25.42 billion in revenue each year. The medical research company earns $7.26 billion in net income (profit) each year or $16.60 on an earnings per share basis.

Amgen employs 24,300 workers across the globe.

The following companies are subsidiares of Amgen: ATL Holdings II Limited, ATL Holdings Limited, Abgenix, Alantos Pharmaceuticals, Amgen (Europe) GmbH, Amgen Canada Inc., Amgen Fremont Inc., Amgen Global Finance B.V., Amgen GmbH Germany, Amgen Holding No. 1 Limited, Amgen K-A Inc., Amgen Manufacturing Limited, Amgen Rockville Inc., Amgen S.A.S., Amgen SF LLC, Amgen Technology, Amgen Technology (Ireland) Unlimited Company, Amgen USA Inc., Amgen Worldwide Holdings B.V., Avidia, Bergamo, BioVex, BioVex Inc., Catherex, DeCODE Genetics, Dezima Pharma, Filgrastim and Pegfilgrastim, Ilypsa, Immunex, Immunex Corporation, Immunex Rhode Island Corporation, KAI Pharmaceuticals, Kinetix Pharmaceuticals, Laboratorio Quimico Farmaceutico Bergamo, MN Pharmaceuticals, Micromet, Nuevolution, Onyx Pharmaceuticals, Onyx Pharmaceuticals Inc., Onyx Therapeutics Inc., Otezla, Synergen, and Tularik.

Amgen was founded in 1980.

The official website for Amgen is www.amgen.com.

Amgen is headquartered at ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA, 91320.

Amgen's mailing address is ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA, 91320. The medical research company can be reached via phone at (805) 447-1000 or via email at [email protected]